General Information of the Compound
| Compound ID |
CP0039930
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
(-)-arterenol
Show/Hide
|
||||||||||||||||||
| Synonyms |
(-)-(R)-Norepinephrine
(-)-Arterenol free base
(-)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(R)-(-)-Norepinephrine
(R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
(R)-Noradrenaline
(R)-Norepinephrine
1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-(9CI)
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
51-41-2
ALBB-006229
Adrenor
Aktamin
D-(-)-Noradrenaline
D53D5E3A-2360-4CA9-8031-6C2CD4062FD5
Ecteinascidins
L-1-(3,4-Dihydroxyphenyl)-2-aminoethanol
L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
L-3,4-dihydroxyphenylethanolamine
L-Noradrenaline
L-Norepinephrine
L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol
L-arterenol
LT03330026
Levarterenol
Levarterenolo
Levarterenolo [DCIT]
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
Nor adrenalin
Nor adrenalin (TN)
Nor-Epirenan
Noradrenalin
Noradrenalina [Italian]
Noradrenaline (JP15)
Noradrenalinum
Norartrinal
Noreinefrina
Noreinefrina [INN-Spanish]
Norepinefrina
Norepinephrine
Norepinephrine (INN)
Norepinephrine Noradrenalin
Norepinephrine [INN:JAN]
Norepinephrine l-Tartrate (1:1)
Norepinephrinum
Norepinephrinum [INN-Latin]
Norepirenamine
Sympathin E
norepinephrine
norepinephrinum
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C8H11NO3
|
||||||||||||||||||
| Molecular Weight |
169.18
|
||||||||||||||||||
| Canonical SMILES |
NC[C@H](O)c1ccc(O)c(O)c1
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C8H11NO3/c9-4-8(12)5-1-2-6(10)7(11)3-5/h1-3,8,10-12H,4,9H2/t8-/m0/s1
Show/Hide
|
||||||||||||||||||
| InChIKey |
SFLSHLFXELFNJZ-QMMMGPOBSA-N
|
||||||||||||||||||
| CAS |
51-41-2
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01089, Alpha-1A adrenergic receptor
Protein ID: PT01650, Alpha-2A adrenergic receptor
Protein ID: PT07536, Alpha-2A adrenergic receptor
Protein ID: PT02026, Alpha-2B adrenergic receptor
Protein ID: PT01598, Alpha-2C adrenergic receptor
Protein ID: PT07687, Alpha-2C adrenergic receptor
Protein ID: PT01494, Beta-2 adrenergic receptor
Protein ID: PT01493, Beta-3 adrenergic receptor
Protein ID: PT01195, D(1A) dopamine receptor
Protein ID: PT01005, D(2) dopamine receptor
Clinical Information about the Compound